Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Demannose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demannose SCHEMBL3397670 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL361547 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL31755099 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL23721809 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL285569 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL25380809 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL6533561 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL25381696 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Galactose SCHEMBL361095 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL30572907 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638489-A1 | PROTEIN-BASED CONJUGATION CARRIERS | Ablynx N.V. (BE) | 2025-10-29 | — | — | EP | claimed |
| WO-2025088546-A1 | FC DOMAIN VARIANTS WITH ENHANCED FC RECEPTOR BINDING | ABLYNX N.V. (BE) | 2025-05-01 | — | — | WO | claimed |
| US-20240415974-A1 | PROTEIN-BASED CONJUGATION CARRIERS | ABLYNX N.V. (BE) | 2024-12-19 | — | — | US | claimed |
| WO-2024133935-A1 | PROTEIN-BASED CONJUGATION CARRIERS | ABLYNX NV (BE) | 2024-06-27 | — | — | WO | claimed |
| EP-4709751-A1 | GLYCOSYLATION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | Sanofi (FR) | 2026-03-18 | — | — | EP | disclosed |
| EP-4638489-A1 | PROTEIN-BASED CONJUGATION CARRIERS | Ablynx N.V. (BE) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025088546-A1 | FC DOMAIN VARIANTS WITH ENHANCED FC RECEPTOR BINDING | ABLYNX N.V. (BE) | 2025-05-01 | — | — | WO | disclosed |
| US-20240415974-A1 | PROTEIN-BASED CONJUGATION CARRIERS | ABLYNX N.V. (BE) | 2024-12-19 | — | — | US | disclosed |
| WO-2024231447-A1 | GLYCOSYLATION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | SANOFI (FR) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024133935-A1 | PROTEIN-BASED CONJUGATION CARRIERS | ABLYNX NV (BE) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415974-A1 | PROTEIN-BASED CONJUGATION CARRIERS | HSPBP1, STAMBP, CRYAB | LMNA 3347/4885L3MBTL1 697/4885TDP1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.